Replicel Is On Fire Lately — Data In Feb.

Xander94

Xander94

Senior Member
My Regimen
Reaction score
4,609
NoMoney said:
After Samumed, Tissuse and Tsuji we will not need Replicel anymore.

I had a conversation witj Tissuse in 2018, they said they try to be much cheaper than Tsuji. (They knew that Tsuji will be very expensive)
So just let us wait. 2021-22 we will get our cure.
Click to expand...
Legit post
 
Desmond_84

Desmond_84

Established Member
Reaction score
359
SadKeanu.jpg


Whats crazy is this was a simple single cell therapy.

What Tsuji and Lauster are proposing are infinitely more complex both in terms of tissue engineering and successful transplantation. Complexity introduces risks which will require a significant amount of tweaking and safety checks. This will require at least 5-7 years of solid human trials before it gets the green light. And that's only if they don't have to go back to the drawing board because of a low yield or low response rate, etc.

Well ladies and gentlemen, the waiting game is upon us once again and soon 2030 will be designated as the year of cure.

CB seems to be the only feasible treatment coming in the next 3 years.
 
RolfLeeBuckler

RolfLeeBuckler

Experienced Member
My Regimen
Reaction score
984
NoMoney said:
For all between NW2 and Norwood 4 Samumed will be the Cure. (Maybe in addition with Follica)

The Rest will need SHT or Tsuji.
I believe that in 10 years everybody will be able to profit from them.
But if you have 40-70k you can get your cure in the next 5 years, maybe a little bit earlier. SHT wants to be much less than 100k, so i believe this could be realistic.
Click to expand...

Please give us the source that SHT will be much less than 100k in the first years after commercialization
 
C

clarence-forgotpassword

Established Member
My Regimen
Reaction score
64
Desmond_84 said:
View attachment 132955

What Tsuji and Lauster are proposing are infinitely more complex both in terms of tissue engineering and successful transplantation. Complexity introduces risks which will require a significant amount of tweaking and safety checks. This will require at least 5-7 years of solid human trials before it gets the green light. And that's only if they don't have to go back to the drawing board because of a low yield or low response rate, etc.
Click to expand...

Lauster is going to regenerate your teeth. Earlier this year there was an interview with his team; "This could be on the market in 3 years, IF everything goes perfectly." Do anyone of them believe anymore believe their own words?
 
RolfLeeBuckler

RolfLeeBuckler

Experienced Member
My Regimen
Reaction score
984
McBald said:
I got a response from Dr Ryoji

Dear *****,


The results will be open in two months.

However, I will not able to inform you personally.

Regards,


***********************************************

Ryoji Tsuboi, MD, PhD
Click to expand...


Ryoji Tsuboi is the Lee Buckler of SHISEIDO

#fuckshiseido
 
S

Super Metroid

Established Member
My Regimen
Reaction score
164
This thing is becoming rather mysterious, since we are waiting for trial data, or any news for that matter, for at least two years. Earlier test results gave showed a maintenance with some regrowth in a study that tested for safety rather that efficacy.

One would say that even if those results are the best Shiseido can do, it would still be worthwhile to market if no side effects are encountered as it would still beat fina + minoxidil. Any reason why Shiseido doesn't just continue RCH-01? If they would have abandoned the tech, the could just announce that right?
 
T

Tom4362

Established Member
My Regimen
Reaction score
513
There have been reports (idk if legit) that the trial only ended around july last year, so maybe they are still processing the results. Lets hope this is the case
 
M

MeDK

Experienced Member
My Regimen
Reaction score
414
Tom4362 said:
There have been reports (idk if legit) that the trial only ended around july last year, so maybe they are still processing the results. Lets hope this is the case
Click to expand...

RCH-01 – RepliCel’s cell therapy for the treatment of Androgenic Alopecia has been the subject of a successful phase 1 trial in Europe and a clinical study now complete in Japan. Shiseido is expected to announce soon whether it will commercially launch the product in Japan or conduct further development and clinical testing. RepliCel will not plan for a phase 2 clinical trial of this product until it has the RCI-02 injector commercially available to use in such a trial and it has clarity from Shiseido regarding its plans for the product in Japan.

Partnership with Shiseido – The dispute regarding the status of the agreement between Shiseido and RepliCel, for the license of RCH-01 in Asia, remains unresolved but is not the subject of any litigation or arbitration. RepliCel maintains the Agreement remains intact and has recently demanded that Shiseido share the data from the recently completed study of RCH-01 in Japan. With the completion of the Japanese RCH-01 study earlier this year, RepliCel is now actively engaging Shiseido to deliver the study data and reach a resolution to the dispute between the parties. RepliCel is eager to end the ongoing dispute and work with Shiseido to commercialize RCH-01.

from replicel them self, it have been quoted loads of times.
 
You must log in or register to reply here.
Community platform by XenForo® © 2010-2023 XenForo Ltd.
Top